Abiopharma

🔍 Gilliam Joseph E (Executive)

Company: GLAUKOS Corp (GKOS)

Report Date: 2026-08-11

Detailed Transactions and Holdings:

• Acquired 10,000 shares of Common Stock at $48.46 per share (Direct)
  Date: 2026-08-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 82,588.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 20,000 shares of Common Stock at $55.18 per share (Direct)
  Date: 2026-08-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 102,588.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 20,000 shares of Common Stock at $55.18 per share (Direct)
  Date: 2026-08-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 122,588.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 10,000 shares of Common Stock at $48.46 per share (Direct)
  Date: 2026-08-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 132,588.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 27,963 shares of Common Stock at $178.89 per share (Direct)
  Date: 2026-08-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 104,625.00 | transaction_form_type: 4 | Footnotes: F2, F1
• Sold 32,037 shares of Common Stock at $180.49 per share (Direct)
  Date: 2026-08-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 72,588.00 | transaction_form_type: 4 | Footnotes: F3, F1
• Sold 20,000 shares of Stock Option (Right to Buy) at $55.18 per share (Derivative)
  Date: 2026-08-11 | Code: M | Expires: 2032-03-24 | equity_swap_involved: 0 | shares_owned_after: 51,475.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 20,000 shares of Stock Option (Right to Buy) at $55.18 per share (Derivative)
  Date: 2026-08-11 | Code: M | Expires: 2032-03-24 | equity_swap_involved: 0 | shares_owned_after: 33,118.00 | transaction_form_type: 4 | Footnotes: F5, F6
• Sold 10,000 shares of Stock Option (Right to Buy) at $48.46 per share (Derivative)
  Date: 2026-08-11 | Code: M | Expires: 2033-03-22 | equity_swap_involved: 0 | shares_owned_after: 26,751.00 | transaction_form_type: 4 | Footnotes: F7
• Sold 10,000 shares of Stock Option (Right to Buy) at $48.46 per share (Derivative)
  Date: 2026-08-11 | Code: M | Expires: 2033-03-22 | equity_swap_involved: 0 | shares_owned_after: 26,751.00 | transaction_form_type: 4 | Footnotes: F8

Footnotes:

• F1: Includes 41,983 restricted stock units that have not yet vested or been delivered to the Reporting Person and and 225 stock units purchased by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
• F2: This transaction was executed in multiple trades at prices ranging from $178.60 to $179.58). The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F3: This transaction was executed in multiple trades at prices ranging from $179.68 to $180.60). The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F4: Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period.
• F5: Represents a portion of an option to purchase shares of common stock previously granted by the Issuer to the Reporting Person on March 24, 2022 in connection with his promotion to President and Chief Operating Officer, the vesting of which was subject to the Issuer's achievement of certain multi-year performance goals.
• F6: Total amount reported has been adjusted to correct a typographical error made in a Form 4 report filed by the Reporting Person on March 17, 2025, in which 13,721 stock options earned were erroneously reported as 13,271 stock options.
• F7: These options vest over four years from the grant date, with 25% vesting on the first anniversary of the grant date and the remaining amount vesting in equal monthly installments over the following three years.
• F8: Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 22, 2023, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period.